Author Correction: Adjuvant Nivolumab, Capecitabine or the Combination in Patients with Residual Triple-negative Breast Cancer: the OXEL Randomized Phase II Study
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.